<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795166</url>
  </required_header>
  <id_info>
    <org_study_id>DAS-7530</org_study_id>
    <secondary_id>U1111-1277-8275</secondary_id>
    <nct_id>NCT05795166</nct_id>
  </id_info>
  <brief_title>A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland</brief_title>
  <acronym>ExplorEUEast</acronym>
  <official_title>A Multicentre, Observational Study to Understand the Distribution of Obesity Classes and Obesity Related Comorbidities (ORCs) in People With Obesity Within a Real World Population in Czech Republic, Hungary and Poland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to understand the distribution of different obesity classes and obesity&#xD;
      related diseases (diseases that present along with obesity) in patients with body mass index&#xD;
      (BMI) â‰¥ 30 kg/m^2.&#xD;
&#xD;
      Participants will be asked to give information about their health. They will continue their&#xD;
      normal way of life and will not get any medication or additional medical test other than&#xD;
      those prescribed to you by their doctor. Participation in the study will last for about 1&#xD;
      day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2023</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with at least one obesity related comorbidity of interest for obesity classes I, II and III pooled across all countries</measure>
    <time_frame>At the time of enrolment (Day 1)</time_frame>
    <description>% patients with obesity</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>People with obesity</arm_group_label>
    <description>Patients with obesity coming into the clinic as part of routine visit to their treating physician/general practitioner</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>No treatment given</description>
    <arm_group_label>People with obesity</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with obesity coming into the clinic as part of routine visit to their treating&#xD;
        physician/general practitioner&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent obtained before any study-related activities (study-related&#xD;
             activities are any procedure related to recording of data according to the protocol).&#xD;
&#xD;
          2. Male or female, age greater than or equal to 18 years at the time of&#xD;
             inclusion/enrolment in the study.&#xD;
&#xD;
          3. BMI greater than or equal to 30 Kg/m^2 as measured at the inclusion in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous participation in this study. Participation is defined as having given&#xD;
             informed consent in this study.&#xD;
&#xD;
          2. Mental incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or cooperation as judged by physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 2834)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

